申请人:BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
公开号:US20200030291A1
公开(公告)日:2020-01-30
The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.